Mitiglinide

Mitiglinide

Clinical data
Trade names	Glufast
AHFS/Drugs.com	International Drug Names
Routes of administration	By mouth (tablets)
ATC code	A10BX08 (WHO)
Identifiers
IUPAC name (−)-(2S,3a,7a-cis)-α-Benzylhexahydro-γ-oxo-2-isoindolinebutyric acid
CAS Number	145375-43-5 N
PubChem CID	121891
DrugBank	DB01252 Y
ChemSpider	108739 Y
UNII	D86I0XLB13
KEGG	D01854 Y
ChEMBL	CHEMBL471498 Y
Chemical and physical data
Formula	C19H25NO3
Molar mass	315.41 g/mol
3D model (JSmol)	Interactive image
SMILES O=C(O)[C@@H](Cc1ccccc1)CC(=O)N3C[C@H]2CCCC[C@H]2C3
InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1 Y Key:WPGGHFDDFPHPOB-BBWFWOEESA-N Y
NY (what is this?)

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium K_ATP channels in pancreatic β cells.

Mitiglinide is delivered in tablet form.